Jinwon Life Sciences Files Patent Application for GLS-1200 to Prevent COVID-19 Virus Infection
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 22nd that it has jointly filed a patent application with the University of Pennsylvania to the United States Patent and Trademark Office (USPTO) for the use of GLS-1200, which received FDA Phase 2 approval as a treatment for chronic sinusitis, to prevent infections caused by other viruses including COVID-19 and influenza.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- SpaceX Pursues 'Largest Ever' Mega IPO... Profitability of Space Business Still Unclear
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "The joint research team has obtained experimental results showing that GLS-1200 prevents viral cell infection, leading to this patent application," and added, "Our company holds exclusive worldwide rights to this patent."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing 90 Degrees These Days Actually Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
